Objective. Levels of circulating cytokines are elevated in inflammatory diseases.
Introduction
Rheumatoid arthritis (RA) is an inflammatory disease of the human skeleton. The imbalance between pro-and anti-inflammatory cytokines in affected joints leads to infiltration of the synovium by immune cells, cartilage damage, and loss of subchondral bone. These bone erosions are governed by pro-inflammatory cytokines, which shift the balance between osteoblastic and osteoclastic activities towards resorption (1, 2) .
Osteoclasts are multinucleated cells of haematopoietic origin and form by fusion of monocyte/macrophage lineage progenitor cells. Two growth factors, haematopoietic growth factor macrophage colony-stimulating factor (M-CSF) and receptor activator of nuclear factor κB ligand (RANKL), are essential and sufficient for osteoclastogenesis.
RANKL binds to RANK on the surface of haematopoietic progenitor cells, activating a signal cascade through tumor necrosis factor receptor-associated factors (TRAFs) that leads to the downstream activation of inhibitor of NF-κB kinase (IKK), c-Jun N-terminal kinase (JNK), p38, extracellular signal-regulated kinase (ERK), and Src (2) . Binding of RANKL to RANK is blocked by osteoprotegerin (OPG), a decoy receptor for RANKL.
Physiologically, the RANKL:OPG ratio governs the biological efficacy of RANKL and its action on osteoclastogenesis. Besides M-CSF and RANKL, numerous cytokines, such as tumor necrosis factor alpha (TNFα), contribute to the modulation of osteoclast development. TNFα stimulates osteoclast differentiation indirectly by modulating the RANKL and OPG levels in stromal cells and directly by acting on osteoclast progenitor cells (OPC) in synergism with RANKL (3, 4) . In vitro, osteoclasts differentiate from bone marrow cells (BMC) grown in culture media supplemented with M-CSF and RANKL, or in coculture of BMC or OPC and osteoblast lineage cells. Upon stimulation with 1,25-dihydroxyvitamin D 3 [1, 25(OH) 2 
], RANKL is upregulated in mesenchymal cells, while OPG levels are attenuated (5, 6) .
In the microenvironment of the bone marrow, immune cells interact with bone cells to modulate their differentiation and activity. In the inflamed joints of patients with RA, activated T-cells secrete osteoclastogenic cytokines, including soluble RANKL, TNFα, interleukin (IL-)6, granulocyte-macrophage colony stimulating factor (GM-CSF), and IL-17A (1, 7, 8) . Furthermore, T-cells trigger macrophages, fibroblasts, and endothelial cells to release pro-inflammatory cytokines, resulting in increased levels in the synovial fluid (9) (10) (11) . TNFα, IL-1, and IL-17A are targeted in RA therapies (11) ; inhibitory antibodies against these cytokines and combinations thereof attenuate both synovial inflammation and subchondral bone resorption (12, 13) .
TNFα and IL-17A are potent inducers of GM-CSF release by mesenchymal cells (14, 15) . GM-CSF is a member of the family of haematopoietic growth factors, which were originally identified by their capacity to induce colony formation in granulocytes and macrophages in vitro (16, 17) . M-CSF and GM-CSF control the proliferation, differentiation, activation, and survival of monocyte/macrophage lineage cells (17) .
Studies on M-CSF-deficient op/op mice demonstrated this factor to control the development of most non-inflammatory macrophage populations and osteoclasts. M-CSF-independent macrophages, mainly involved in inflammatory and immune responses, are not affected by the op/op mutation (18, 19) . M-CSF is constitutively expressed by multiple cell types and circulates in the blood. GM-CSF is not detectable in physiological conditions, but levels rise dramatically during immune response and inflammation (17) . Besides its growth factor-like action in 5 granulocytic cells and macrophages, GM-CSF promotes the maturation of dendritic cells, in particular in inflammation (20) . Neutralizing antibodies against GM-CSF have been successfully used in various models to treat autoimmune or inflammatory diseases, including collagen-induced arthritis (17, 21) .
In the present study, the roles of IL-17A and GM-CSF in osteoclast differentiation and activity were investigated in vitro, with a focus on the osteoclastogenic potential of GM-CSF-treated OPC. The data demonstrate that IL-17A, in synergism with TNFα and 1,25(OH) 2 D 3 , stimulates osteoblasts to release GM-CSF. Exposure of OPC to GM-CSF leads to a dendritic cell-like phenotype. Upon stimulation with M-CSF/RANKL, these cells differentiate into active osteoclasts that are able to dissolve a calcium phosphate (CaP) matrix. 7 supplemented with 1,25(OH) 2 D 3 (10 -8 M; Sigma-Aldrich), recombinant murine TNFα (0.5 ng/ml; Genentech, San Francisco, USA), and IL-17A (0.1, 1, 5, 10, or 50 ng/ml; PeproTech, London, UK). After 3 days, the medium was replaced, and multinucleated osteoclasts were visible after 4 to 5 days.
Inhibitory antibodies (BD, Allschwil, CH) were used to assess the effects of TNFα and GM-CSF on osteoclastogenesis. Rat anti-mouse antibodies against TNFα and GM-CSF were added to the cultures at 1 µg/ml. Control cultures were treated with the respective isotype controls (rat IgG1 κ Isotype Ctrl and rat IgG2a κ Isotype Ctrl). In cultures with anti-TNFα, RANKL (10 ng/ml, recombinant human RANKL, PeproTech) was added to allow osteoclast formation. Osteoclast activity assay. The activity of osteoclasts was assessed by their capacity to dissolve amorphous CaP. As described previously (23) , sterile-filtered solutions of 0.12 M Na 2 HPO 4 and 0.2 M CaCl 2 in 50 mM Tris/HCl, pH 7.4, were left in an atmosphere of 5% CO 2 at 37°C overnight. Then, 45 [Ca]Cl 2 (PerkinElmer, Schwerzenbach, CH) was added to a final concentration of 8000 Bq per well. Equal volumes were mixed in 50 ml tubes and CaP precipitated. The slurry was washed with water twice, resuspended with 10 ml of water per 1 ml of slurry, and 200 µl of the suspension was added into the wells of 48-well plates. The plates were dried at room temperature for 3 days and baked at 80°C for 3 h. Before use, the CaP layers were coated with αMEM/30% FBS overnight.
Osteoclasts were generated in vitro from OPC as described above. Mature osteoclasts were resuspended in 500 µl of medium per dish and seeded into the CaP-coated wells (50 µl of cell suspension per well) in medium supplemented with M-CSF (30 ng/ml), RANKL (20 ng/ml), and HCl (15 mM). After 24 h, the supernatants were collected and 45 [Ca] was measured. The cells were lysed for measurement of total TRAP activity.
Magnet-activated cell sorting (MACS) and flow cytometry. GM-CSF-dependent
progenitor cells (4 × 10 8 ) were incubated with anti-CD11c magnetic beads at 4°C for 15 min and loaded onto columns that were placed in a magnetic cell separator (all from Miltenyi Biotech, Bergisch Gladbach, Germany). Positive (adherent) and negative (nonadherent) cell fractions were collected and counted. The individual cell fractions were differentiated into osteoclasts in culture media supplemented with M-CSF/RANKL as 
Results

IL-17A in synergism with TNFα inhibits the formation of osteoclasts in cocultures.
To assess the effects of IL-17A, TNFα, 1,25(OH) 2 D 3 , and various combinations thereof on osteoclast formation in vitro, wt OPC were cocultured with osteoblasts from either wt mice or p55TNFR −/− /p75TNFR −/− mice. In cocultures with C57Bl/6J wt osteoblasts supplemented with 1,25(OH) 2 D 3 /TNFα, IL-17A inhibited osteoclastogenesis, reducing the number of osteoclasts by ≥90% at 1 ng/ml. In cocultures with C57Bl/6J wt osteoblasts in the absence of TNFα, only few osteoclasts developed, and IL-17A enhanced osteoclast formation by a factor of 6, reaching approx. 20% as compared to 1,25(OH) 2 D 3 /TNFα (Suppl. Fig. 1A ). In cocultures with osteoblasts from p55TNFR −/− /p75TNFR −/− mice, the inhibitory effect of IL-17A on osteoclast development was largely abolished (Suppl. Fig. 1B ).
Concomitant action of TNFα and GM-CSF is required for IL-17A-mediated
inhibition of osteoclastogenesis. To assess the specific roles of TNFα and GM-CSF in the IL-17A-mediated inhibition of osteoclastogenesis in vitro, blocking antibodies against TNFα and GM-CSF were added to the cocultures. Since only low numbers of osteoclasts were formed in cocultures with osteoblasts from C57Bl/6J mice in the absence of TNFα, exogenous RANKL (10 ng/ml) was added together with anti-TNFα antibodies and with the respective controls ( Fig. 1A,B ).
Blocking of TNFα, in the presence of RANKL, abrogated the inhibition of osteoclastogenesis by IL-17A ( Fig. 1A) , while in cultures with IgG control antibodies, osteoclast development was inhibited by 95% by IL-17A at 1 ng/ml, irrespective of the presence of RANKL (Fig. 1B,D) . In cocultures with media supplemented with TNFα, 13 without 1,25(OH) 2 D 3 , osteoclast formation was reduced to approx. one third, but the inhibitory effect of IL-17A was unabated ( Fig. 1B) . On the other hand, IL-17A was ineffective in cocultures with media supplemented with 1,25(OH) 2 D 3 alone (Fig 1A,B) .
Attenuation of the IL-17 effect was also observed upon addition of anti-GM-CSF antibodies to cocultures grown with TNFα and 1,25(OH) 2 D 3 (Fig. 1C) . In culture media without exogenous TNFα, IL-17A induced an increase in the number of osteoclasts (Fig.   1C,D) . Fig. 2A) . Transcript levels of the dendritic cell marker CD11c were dose-dependently increased by exogenous GM-CSF, independently of the presence of M-CSF (Fig. 2B ). Similar expression patterns were observed for DC-STAMP ( Fig. 2C ) and OC-STAMP (Fig. 2D ). Levels of cFMS mRNA were dose-dependently decreased with increasing concentrations of GM-CSF ( Fig. 2E ). CSF2R transcripts were 14 upregulated by GM-CSF, while the presence of M-CSF prevented this increase (Fig.   2F ).
Osteoblasts from C57BL/6J
OPC precultured with M-CSF, GM-CSF, or M-CSF/GM-CSF give rise to osteoclasts.
OPC were cultured with M-CSF (30 ng/ml), GM-CSF (10 ng/ml), or M-CSF/GM-CSF.
The potential of the OPC to develop into osteoclasts was assessed by subsequent culture with M-CSF (30 ng/ml)/RANKL (20 ng/ml). Starting on day 0 of osteoclast culture, cells were collected daily and total RNA was prepared for qRT-PCR.
In M-CSF-treated OPC, F4/80 transcript levels were twofold higher than those in OPC treated with GM-CSF and M-CSF/GM-CSF at day 0. Thereafter, F4/80 transcript levels decreased before an induction at day 5 of the osteoclast culture (Fig. 3A) . OPC pretreated with GM-CSF and M-CSF/GM-CSF were characterized by increased mRNA levels of CD11c (Fig. 3B ), DC-STAMP (Fig. 3C) Expression of transcripts encoding the osteoclast transcription factor NFATc1 (Fig. 3D) preceded the expression of OC markers and the development of OC. CTR mRNA levels ( Fig. 3E ) increased with cell differentiation and correlated with the numbers of osteoclasts ( Fig 3F) .
Osteoclasts generated from M-CSF, GM-CSF, and M-CSF/GM-CSF-treated OPC
dissolve CaP in vitro. The capacity of osteoclasts generated from M-CSF, GM-CSF, and M-CSF/GM-CSF dependent OPC to dissolve CaP mineral was assessed by seeding mature cells onto a layer of 45 Ca-spiked amorphous CaP (Fig. 4A ). Osteoclasts developed faster from M-CSF-than from GM-CSF-and M-CSF/GM-CSF-treated OPC (Fig. 4B ). Upon transfer of mature OPC onto the CaP layers, TRAP activity was the same in all 3 groups in the cell suspension and after 1 h of adherence (Fig. 4C ). Within 24 h, total TRAP activity from M-CSF-dependent OPC decreased by 20%, while increasing by more than 50% in cultures of osteoclasts from GM-CSF-and M-CSF/GM-CSF-dependent OPC (Fig. 4C) . Cells in the latter cultures released twofold higher amounts of 45 Ca than M-CSF-dependent OPC (Fig. 4D) . Despite the increased dissolution of CaP, the release of 45 Ca per TRAP after 24 h was similar among all osteoclast populations (Fig. 4D ).
CD11c + , GM-CSF-dependent OPC give rise to active osteoclasts. To check whether
the CD11c + dendritic-like cells or a CD11csubpopulation of the GM-CSF-dependent OPC give rise to osteoclasts, CD11c + cells were isolated by MACS (CD11c bright ).
Unsorted cells, CD11c dim , and CD11c bright cells were differentiated into osteoclasts and their capacity to dissolve CaP was assessed. In total GM-CSF-dependent OPC (F1) and in control cells with anti-CD11c magnetic beads (F2), ca. 70% of the cells were CD11c + , with median fluorescence intensities (MFI) of the positive cells at 10,796 and 10,110 respectively. The negatively (flow through) sorted cells were 55% positive (CD11c dim ; F3; MFI 6,267), and 98% of the positively (adherent) sorted cells (CD11c bright ; F4; MFI 24,978) expressed CD11c (Fig. 5A ). All populations gave rise to TRAP-positive, multinucleated osteoclasts (Fig. 5B) , with similar trends being observed for total TRAP activity ( Fig. 5C ) and dissolution of CaP mineral (Fig. 5D ).
Osteoclasts differentiated from GM-CSF-treated progenitors have a higher proliferation potential than those developed from M-CSF-treated progenitors.
To investigate whether the difference in osteoclast development from M-CSF-and GM-CSF-dependent OPC is correlated with cell proliferation, the cells were labeled at day 3 or day 4 with EdU, and nuclear labeling was quantitated at days 5 and 6 of culture.
Nuclei were visualized with Hoechst ( Fig. 6A,C,E) , and mitotic nuclei with EdU ( Fig.   6B ,D,F). The percentage of labeled nuclei was threefold higher in osteoclasts from GM-CSF-and M-CSF/GM-CSF-dependent OPC than in those from M-CSF-dependent OPC after the addition of EdU to the cultures at day 3, and twofold higher when EdU was added at day 4 ( Fig. 6G ). After six days in culture, the total number of nuclei was doubled in osteoclasts differentiated from OPC dependent on GM-CSF and M-CSF/GM-CSF as compared to osteoclasts derived from M-CSF-dependent OPC (Fig. 6H ).
Discussion
The present study shows that IL-17A in synergy with TNFα and 1,25(OH) 2 as an inhibitor of osteoclast development (14, 15, 25) . This specific effect of IL-17A on osteoblast lineage cells contrasts the previously described dual effects of TNFα; inhibiting osteoclast development indirectly by inducing osteoblast lineage cells in synergy with 1,25(OH) 2 D 3 to release GM-CSF (14) , while stimulating osteoclastogenesis through a direct effect on OPC (3, 4, 26, 27) . Haematopoietic growth factors act in sequence on haematopoietic stem cells and, depending on the factor, cells differentiate towards specific lineages (28, 29) . GM-CSF acts on early progenitor cells and blocks their differentiation towards the monocyte/macrophage and osteoclast lineages (15) . In the presence of GM-CSF, the cells fail to raise levels of RANK, consequently leading to interruption of RANK/RANKL signaling. Therefore, the addition of exogenous RANKL to cocultures could not abrogate the inhibitory effect of GM-CSF. Several studies have shown that the inhibition of osteoclastogenesis by GM-CSF prevents the induction of c-Fos and Fra-1, and indeed, overexpression of c-FOS by retroviral infection rescued osteoclast differentiation despite the presence of GM-CSF (14, 30) . In a later differentiation stage, characterized by high levels of RANK, GM-CSF no longer affects osteoclastogenesis (15, 25) .
The second part of the study provides evidence that GM-CSF-dependent OPC express a dendritic cell-like phenotype, characterized by the expression of CD11c and DC-STAMP, but not to undergo irreversible commitment to the dendritic cell lineage. Upon exposure to M-CSF/RANKL, CD11c and DC-STAMP transcript levels were decreased in GM-CSF-pretreated OPC, before they developed into osteoclasts and reassumed the expression of DC-STAMP.
The effect of GM-CSF on OPC depends on its concentration. In cultures in the presence of GM-CSF in the picogram range, cells remained CD11c -, even though differentiation to osteoclasts was blocked (14) . Treatment of OPC with M-CSF and GM-CSF in the nanogram range increased CD11c expression dose-dependently, with a concomitant loss of the pan-macrophage marker F4/80. The concentration-dependent action of GM-CSF on haematopoietic cells may be caused by differential activation of signaling pathways, analogous to the action of transforming growth factor β (TGFβ) on haematopoietic cells (31) . DC-STAMP is required for the regulation of dendritic cell activity and the maintenance of immune self-tolerance (32, 33) , but it is also present on late OPC and, together with OC-STAMP, participates in cell fusion (34, 35) . In OPC, levels of DC-STAMP and OC-STAMP transcripts increased in parallel with those of CD11c. In cultures of GM-CSFpretreated OPC, DC-STAMP and OC-STAMP mRNA levels decreased and then increased again with osteoclast maturation. This loss of DC-STAMP and OC-STAMP expression during osteoclast culture indicates that GM-CSF pretreated progenitors first lose their dendritic cell-like phenotype before fusing into multinucleated osteoclasts.
Based on the expression of osteoclast transcription factor NFATc1 and on the time course of the detection of osteoclasts in culture, osteoclasts from GM-CSF-pretreated OPC do not differ from osteoclasts generated from M-CSF-pretreated OPC, while their differentiation is delayed. This contrasts a recent report postulating that dendritic cells directly fuse to form osteoclasts, so-called DC-OC (36) . However, no specific markers for DC-OC, which would allow distinguishing them from "normal" osteoclasts, are available at present. It has been shown that immature dendritic cells generated from human blood monocytes differentiate into functional osteoclasts in the presence of M-CSF and RANKL (37) . Furthermore, conventional dendritic cells were found to resolve the osteopetrotic phenotype within one month when injected into osteopetrotic oc/oc mice defective in osteoclast resorption (38). The differentiation mechanisms, however, were not elucidated in these studies, and taking into account the time frame before effects were observed, it is likely that these cells underwent dedifferentiation before developing into osteoclasts.
Osteoclasts from GM-CSF-treated OPC showed the same capacity to dissolve mineral as osteoclasts from M-CSF-treated OPC, but are delayed in differentiation. After transfer onto CaP at day 5, TRAP activity further increased, which was in contrast to osteoclasts from M-CSF-pretreated OPC, whose number and TRAP activity decreased simultaneously. Thus, osteoclasts from GM-CSF-pretreated progenitors had more time to proliferate in the coculture and to leave the cell cycle at a later time point than did M-CSF-pretreated OPC, resulting in a higher number of late progenitors capable of differentiation and fusion. These findings are in accordance with studies demonstrating the proliferative effects of GM-CSF on haematopoietic progenitor cells (39) (40) (41) .
The present study provides evidence for the action of GM-CSF as a positive modulator of osteoclastic activity in the context of inflammatory disease, despite its direct inhibitory effect in vitro on osteoclastogenesis. Furthermore, it confirmed that cells expressing the dendritic cell marker CD11c are not irreversibly committed to the dendritic cell lineage, but can give rise to osteoclasts upon stimulation with M-CSF/RANKL (25, 37, 38) .
Osteoclasts and dendritic cells derive from the same myeloid progenitors, and differentiation has been shown to be regulated by M-CSF and GM-CSF (30). However, as described above, the action of GM-CSF depends on the timing and the differentiation state of the cells, and GM-CSF overrides M-CSF signaling in early haematopoietic progenitors (39) . Besides its systemic effects, GM-CSF secreted by activated T-cells in inflamed joints may also locally increase the number of dendritic cells, which may serve as precursors of osteoclasts and contribute to the exacerbated osteoclastogenesis in RA (42) (43) (44) .
It has been postulated previously that OPC and osteoclasts may develop and mature in different physical compartments in the organism (14) . In circulation, elevated levels of GM-CSF, as they occur in inflammatory diseases, act by increasing the proliferation of haematopoietic progenitor cells (45) . It was reported that the pool of CD11c + cells is expanded in RA patients (46, 47) . Upon recruitment to the bone, the composition of the 
